Table 1.
Studies of BRAF-targeted therapies in mCRC
| Studies (Author) | Treatment | ORR | PFS (months) |
|---|---|---|---|
| Kopetz et al26 | Vemurafenib | 5% | 2.1 |
| Falchook et al78 | Dabrafenib | 10% | NR |
| Corcoran et al31 | Dabrafenib + trametinib | 12% | 3.5 |
| Yaeger et al32 | Vemurafenib + panitumumab | 13% | 3.2 |
| Tabernero et al33 | Vemurafenib + cetuximab | 20% | 3.2 |
| Atreya et al34 | Dabrafenib + panitumumab | 10% | 3.4 |
| Atreya et al34 | Dabrafenib + panitumumab + trametinib | 26% | 4.1 |
| Tabernero et al35 | Encorafenib + cetuximab | 23% | 4.0 |
| Tabernero et al35 | Encorafenib + cetuximab + alpelisib | 32% | 4.4 |
| Hong et al36 | Vemurafenib + cetuximab + irinotecan | 35% | 7.7 |
Abbreviations: mCRC, metastatic colorectal cancer; ORR, overall response rate; PFS, progression-free survival; NR, not reported.